Betting on BTK Inhibitors in CLL: Where are We Now and Where are We Going?

November 4, 2020

This initiative is targeted to addressing the professional practice of pharmacists in hospitals, health systems, ambulatory care clinics, and other settings. Attendees of this activity will gain insight into the latest clinical and scientific advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKis), including the latest approvals, the most current safety and efficacy data, and expert insights into addressing challenges of CLL treatment using BTKis. Using a case-based approach, discussion on anticipating and managing adverse events, therapy selection, and improving adherence will be incorporated into this cutting-edge activity.

Supported by an independent educational grant from AstraZeneca.

Target Audience

This activity is designed to meet the educational needs of hospital and health-system pharmacists, pharmacy directors, and pharmacy residents. 

Learning Objectives

  1. Describe the role of the BCR (B-cell receptor) pathway in malignant B-cell survival.
  2. Explore the therapeutic rationale for targeting the BCR pathway in CLL and other B-cell malignancies.
  3. Assess the latest safety and efficacy data for BTKis (BTK inhibitors) in TN (treatment-naïve) and R/R (relapsed/refractory) CLL and examine strategies to overcome resistance seen in these agents.
  4. Using a case-based approach, appraise effective strategies to integrate BTK inhibitors into the CLL treatment paradigm, recognize and appropriately manage adverse events, and answer challenging clinical issues pharmacists may encounter in their practice.
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 Participation
Course opens: 
10/01/2020
Course expires: 
11/04/2020
Event starts: 
11/04/2020 - 6:00pm
Event ends: 
11/04/2020 - 7:30pm
Rating: 
0

 5  min     Welcome and Introductions/Pre-test
10 min     The BCR Pathway: A Potential Game-Changing Target in CLL
20 min     Addressing Challenges in CLL Treatment: BTK Inhibition-the Past, Present, and Future
15 min     Pharmacist Perspectives: Exploring Current Challenges in CLL Management and Integrating BTKis into Practice
10 min     Q&A/Post-test

Rebecca J. Nelson, PharmD, BCOP 
Clinical Pharmacy Coordinator 
Malignant Hematology 
Moffitt Cancer Center 
Tampa, Florida

Dr. Nelson is the Clinical Pharmacy Coordinator for the Malignant Hematology division at Moffitt Cancer Center and Research Institute.  She currently supervises a team of hematology pharmacists and practices across the inpatient and outpatient setting. She has experience in multiple practice areas, leads numerous process improvement projects, and collaborates with hematologists on research projects within in her institution. She received her Doctor of Pharmacy from Lake Erie College of Osteopathic Medicine School of Pharmacy and her Bachelors of Science in Molecular Biology and Microbiology from the University of Central Florida. She completed two years of post-graduate residency training at Moffitt Cancer Center and went on to receive her Board Certification in Oncology Pharmacy. She is a member of multiple professional organizations and speaks nationally on drug and disease topics.


Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner: 
Vanessa Carranza–has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenter:
Rebecca J. Nelson, PharmD, BCOP–has disclosed that she is a consultant for AbbVie, BTG, and Stemline.

Peer Reviewer:
Benyam Muluneh, PharmD, BCOP, CPP–has no relevant financial relationships to disclose in relation to the content of this activity.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit JA0007101-0000-20-001-L01-P.

Upon completion of a CE request form, pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 Participation
Please login or register to take this course.